DifGen Pharmaceuticals Secures FDA Approval for Generic Mesalamine Extended-Release Capsules
核心洞察
DifGen Pharmaceuticals (搜索) received FDA approval for generic Mesalamine Extended-Release Capsules USP in 250mg and 500mg strengths, therapeutically equivalent to PENTASA®.
The 250mg strength received Competitive Generic Therapy (CGT) designation, marking DifGen's second consecutive first-cycle FDA approval for a complex generic ANDA.
The approval addresses significant pharmacokinetic challenges including high inter-subject variability, low systemic absorption, and unpredictable bioavailability of mesalamine.
DifGen Pharmaceuticals (搜索) LLC announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Mesalamine Extended-Release Capsules USP in 250mg and 500mg strengths. The approved product is therapeutically equivalent (AB-rated) to the reference listed drug PENTASA® (mesalamine) Extended-Release Capsules, with the 250mg strength receiving Competitive Generic Therapy (CGT) designation.
Regulatory Achievement
This approval represents DifGen's second consecutive first-cycle FDA approval for a complex generic ANDA, drawn from what the company describes as a robust, high-barrier pipeline established since its inception. The milestone marks a significant addition to DifGen's growing portfolio of complex generics and reinforces the company's mission to broaden patient access to high-quality, affordable pharmaceutical therapies across the United States.
"When Santa and I founded DifGen, we envisioned 'Difficult and Differentiated Generics' - this approval and imminent launch brings that vision to life," said Ramandeep Singh Jaj, Founder & Co-CEO of DifGen Pharmaceuticals (搜索). "We're proud to expand our portfolio, navigating complex regulatory pathways and bringing high-quality affordable treatments to patients."
Scientific and Manufacturing Challenges
The development of generic mesalamine presented significant pharmacokinetic challenges that required specialized expertise to overcome. Dr. Santhanakrishnan Srinivasan, Founder & Co-CEO of DifGen Pharmaceuticals (搜索), highlighted the complexity of the achievement: "This milestone highlights DifGen's strong scientific, clinical, and regulatory expertise in developing and securing approval of a complex product like Mesalamine that poses inherent pharmacokinetic challenges."
The company's scientific affairs team addressed these challenges by developing a robust manufacturing process and identifying stringent inclusion/exclusion criteria to manage the product's high inter-subject variability, low systemic absorption, and unpredictable bioavailability. These characteristics make mesalamine a particularly challenging compound for generic development, requiring sophisticated approaches to demonstrate bioequivalence to the reference product.
Market Impact
The approval of generic mesalamine extended-release capsules is expected to provide patients with more affordable access to this important therapeutic option. The CGT designation for the 250mg strength recognizes the product's potential to increase competition in the market and provide additional treatment options for patients requiring mesalamine therapy.